On 20 October 2004, orphan designation (EU/3/04/232) was granted by the European Commission to Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy, for biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium for the treatment of glioma.
- What is glioma?
Tumours that begin in brain tissue are known as primary brain tumours. Primary brain tumours are classified by the type of tissue from which they originate, the most common being gliomas, which begin in the glial (supportive) tissue.
Gliomas represent a debilitating and life-threatening condition. Patients affected by gliomas can suffer from severe symptoms of the nervous system, depending on where in the brain the tumour develops.
- What are the methods of treatment available?
Treatment for gliomas depends on a number of factors and encompasses several methods such as surgery, radiotherapy (using high-dose x-rays or other high energy rays to kill cancer cells) or chemotherapy (using drugs to kill cancer cells), as well as some symptomatic treatments. Symptomatic treatments include certain steroid hormones (corticosteroids) to control the effects of raised pressure within the skull, and medication to help control seizures, as required. Methods of treatment of glioma were authorised in the Community at the time of submission of the application for orphan designation.
Biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium might be of potential significant benefit for the treatment of gliomas because it might help to improve the localisation of the radiotherapy to the glioma. The assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- What is the estimated number of patients affected by the condition*?
According to the information provided by the sponsor, glioma was considered to affect about 46,000 persons in the European Union.
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed based on data from the European Union (EU 25), Norway, Iceland and Lichtenstein. This represents a population of 459,700,000 (Eurostat 2004). This estimate is based on available information and calculations presented by the sponsor at the time of the application.
- How is this medicinal product expected to act?
The product comprises a kit containing an antibody, a number of other proteins and a radioactive element (90-Yttrium). Antibodies are proteins in the body that target specific shapes on the surface of foreign entities, such as bacteria and viruses, but also on abnormal body cells such as cancer cells. In this case, the antibody is intended to target a protein (tenascin), which is present in particular in the space that exists between the tumour cells and is therefore expected to accumulate in the tumour. The other proteins in the kit are administered to clear the excess antibody from the rest of the body and assist in targeting the radioactive element (90-Yttrium) to the glioma. The purpose of the targeting of the radioactive element inside the tumour mass is to kill the maximum tumour cells and minimise the amount of rays in the rest of the body.
- What is the stage of development of this medicinal product?
The evaluation of the effects of biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium in experimental models is ongoing. At the time of submission of the application for orphan designation, no clinical trials in patients with glioma were initiated. The medicinal product was not marketed anywhere worldwide for glioma or designated as orphan medicinal product elsewhere for this condition, at the time of submission. According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 9 September 2004 a positive opinion recommending the grant of the above mentioned designation.
- Opinions on orphan medicinal products designations are based on the following cumulative criteria:
- the seriousness of the condition,
- the existence or not of alternative methods of diagnosis, prevention or treatment and
- either the rarity of the condition (considered to affect not more than five in ten thousand persons in the Community) or the insufficient return of development investments.
Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation.
As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/04/232: Public summary of positive opinion for orphan designation of biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium for the treatment of glioma||(English only)||03/01/2006|
|Active substance||Biotinylated anti-tenascin monoclonal antibody for use with 90-Yttrium|
|Disease/condition||Treatment of glioma|
|Date of decision||20/10/2004|
|Orphan decision number||EU/3/04/232|
Review of designation
Sponsor’s contact details:
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Viale Shakespeare 47
Telephone: +39 06 91 39 33 03
Telefax: +39 06 91 08 260
Patients’ associations contact points:
3 Bath Place
Telephone: +44 20 76 96 90 03 / 0808 800 1234 (freephone for UK)
Telefax: +44 20 76 96 90 02
Deutsche Krebshilfe e.V.
Telephone: +49 2 28 72 99 00
Telefax: +49 22 87 29 90 11
Ligue Nationale Contre le Cancer
13 Av. de la Grande Armee
Telephone: +33 1 45 00 00 17
Tefefax: +33 1 45 00 63 06